Independent Market Access and Reimbursement Risk Assessment.
Built by former payers, HTA reviewers, and Industry Experts.
As of October 2026, MARA’s assessment finds Jaypirca / Pirtobrutinib’s reimbursement risk concentrated in comparator selection, with evidence quality and robustness a strength; the current MARA Rating and full rationale are available in the report.
The assessment also weighs patient population and subgroups: how closely the trial population matches the patients who would receive the drug in practice; payers often restrict funding to the groups where the evidence is strongest. The strength recorded in evidence quality and robustness carries weight because that domain asks how solid the underlying evidence is on its own terms — trial design, size and endpoints — before any question of price is reached.
This rating sits within MARA’s Oncology coverage, alongside 168 other independently assessed treatments in the same area.
The MARA Rating® is an independent opinion of a drug’s market access pharma risk profile and is provided for informational purposes only—not as investment, medical, legal or any other type of advice. See our full disclaimer here.